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Abstract: Diabetes mellitus (DM) is considered a global pandemic, and the incidence of 
DM continues to grow worldwide. Nutrients and dietary patterns are central issues in the 
prevention, development and treatment of this disease. The pathogenesis of DM is not 
completely understood, but nutrient-gene interactions at different levels, genetic predisposition 
and dietary factors appear to be involved. Nutritional genomics studies generally focus on 
dietary patterns according to genetic variations, the role of gene-nutrient interactions, gene-
diet-phenotype interactions and epigenetic modifications caused by nutrients; these studies 
will facilitate an understanding of the early molecular events that occur in DM and will 
contribute to the identification of better biomarkers and diagnostics tools. In particular, this 
approach will help to develop tailored diets that maximize the use of nutrients and other 
functional ingredients present in food, which will aid in the prevention and delay of DM and 
its complications. This review discusses the current state of nutrigenetics, nutrigenomics and 
epigenomics research on DM. Here, we provide an overview of the role of gene variants and 
nutrient interactions, the importance of nutrients and dietary patterns on gene expression, 
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how epigenetic changes and micro RNAs (miRNAs) can alter cellular signaling in response 
to nutrients and the dietary interventions that may help to prevent the onset of DM. 
Keywords: diabetes; insulin resistance; pancreatic β cell; gene-nutrient interaction; 
nutrigenetics; nutrigenomics; epigenetics; miRNAs; nutrients; dietary patterns 
 
1. Introduction 
Diabetes mellitus (DM) is a group of metabolic diseases characterized by hyperglycemia, which 
results from defects in insulin secretion, insulin activity or both. DM is associated with the dysfunction 
and failure of different organs, such as the blood vessels, heart and kidneys [1], and this disease is 
considered a global burden [2]. The International Diabetes Federation’s most recent estimates indicate 
that 8.3% of adults (382 million individuals) have diabetes, and the number of individuals with this 
disease is expected to rise beyond 592 million in less than 25 years [2]. The vast majority of cases of 
DM fall into two broad etiopathogenetic categories: type 1 and type 2 DM (T1DM and T2DM, 
respectively). T1DM, previously named insulin-dependent diabetes or juvenile-onset diabetes, results 
from cellular-mediated autoimmune destruction of pancreatic β cells; therefore, patients are dependent 
on exogenous insulin. Individuals with T1DM are considered to have a genetic predisposition, although 
environmental factors, such as dietary components, also contribute to T1DM development [3]. Thus, 
T1DM is the result of a complex interrelation among β cells, the immune system and environmental 
factors in genetically susceptible individuals [3]. T1DM appears predominately in children and young 
adults and affects 5%–10% of diabetic patients [2]. T2DM is chronic disorder caused by insulin secretion 
deficiency and insulin resistance. T2DM is a complex trait that results from the contribution of many 
genes [4], many environmental factors, including diet [5], and the interactions among these genes and 
environmental factors. T2DM is more common among individuals aged 40 to 60 years and accounts for 
most cases of DM (more than 90%) [2]. 
The incidence rates of both types of DM are increasing and their exact causes are not completely 
understood. It seems that interactions between multiple genes and environmental factors may play a role. 
One of these factors is dietary factors. There is evidence supporting the role of nutrient-gene interactions 
in DM pathophysiology [5]. Thus, a greater understanding of potential gene-nutrient interactions may 
be relevant for DM prevention and treatment. 
Nutrigenetics and nutrigenomics are defined as the science of the effects of genetic variation on 
dietary responses and the role of nutrients and bioactive food compounds in gene expression, 
respectively [6]. It is important to note that both terms are closely related but not interchangeable. 
Nutrigenetics research involves genetic inheritance and its variations in the response to nutrients and 
dietary patterns [7], whereas nutrigenomics investigations focus on dietary effects on genome stability, 
epigenome alterations, RNA and miRNA alterations, protein expression and metabolite changes. Both 
fields depend on advances in genomics, transcriptomics, proteomics and metabolomics, as these  
high-throughput technologies enable the analysis of many different genes and their variants, metabolites 
and a large number of nutrients and bioactives present in food and how they affect human metabolism, 
nutritional homeostasis and molecular events involved in nutrition-related diseases, such as diabetes. 
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However, while the application of these technologies is becoming more accessible, analysis of the 
complex large data sets that are generated presents multiple challenges. 
The aim of the present review was to provide insights regarding the role of nutrient-gene interactions 
in DM pathogenesis, prevention and treatment. In addition, we explored how an individual’s genetic 
makeup can affect nutrient metabolism and the response to nutrient intake, potentially leading to DM. 
It is important to promote greater research in this field because these findings will provide a 
framework for the development of genotype-dependent food health promotion strategies and the design 
of dietetic approaches for the prevention and management of DM. This knowledge has begun to provide 
evidence where specific targeted nutritional advice, such as following a Mediterranean Diet, helps to 
decrease cardiovascular risk factors and stroke incidence in people with polymorphisms strongly 
associated with T2DM [8]. 
2. Nutrigenetics Approximation to DM 
Chronic non-communicable diseases (NCD), such as coronary heart disease, high blood pressure, 
cancer or DM, which account for approximately 60% of global mortality [9], tend to aggregate in 
families, and the risk among relatives is higher compared to the general population [10]. Families share 
both genes and environment; however, various families, even those composed of different ethnic groups, 
may live together in the same cities within a homogenous environment. In these situations, individual 
genetic variants or inheritances contribute to NCD susceptibility, such as DM, through the modulation 
of the response to nutrients or diets. In this regard, approximately one decade ago, genome-wide 
association studies (GWAS) revealed certain genomic variants that predisposed individuals to DM [11]. 
Furthermore, GWAS results have also highlighted the importance of dietary variables [12]. 
Genetic variation across the human genome has been recognized as increasingly complex.  
Single-nucleotide polymorphisms (SNPs) are the most common type of genetic variations dispersed within 
or outside a gene region in the human genome. Approximately one decade ago, there were more than  
10 million SNPs reported in public databases [13]. Genetic polymorphisms are normally identified in at 
least 1% of the population, and approximately 54% of these variants are not deleterious mutations [14]. 
In the case of DM, these variants, in general, do not directly cause the disease but alter the risk of 
developing DM [15]. 
Recent GWAS have successfully identified more than 40 independent T1DM-associated tagging SNPs; 
however, the sum of these loci does not fully explain the heritability estimated from familial studies [16]. 
For example, twin studies have shown that for di-zygotic twins, the pairwise T1DM concordance rate is 
10%, whereas for mono-zygotic twins, the concordance rate is approximately 50% [17]. Thus, dietary 
and other environmental factors also influence T1DM incidence and development. These factors 
primarily include the use of breast milk vs. infant formula [18], highly hydrolyzed infant formula vs. 
conventional infant formula [19], early/late exposure to gluten [20] and vitamin D [21]. Interestingly, a 
newly diagnosed child fed a gluten-free diet was shown to remain healthy without insulin therapy for 20 
months [22]. 
Over the last five years, several studies have linked diet/nutrients (mainly dietary fiber), gut 
microbiota and the expression of genes involved in immune responses. It is well known that the diet has 
a profound effect on the gut microbiota. In mice and humans, microbes respond differently to dietary 
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components, and long-term dietary habits have been linked to the abundance of certain microbial  
genera [23]. The gut lumen contains large amounts of nutrients that strongly influence the composition 
of the microbiota, which affects gut immunity. These alterations in gut immunity can precipitate T1DM 
in individuals prone to T1DM. It has also been observed that diabetes-prone BioBreeding (BBdp) rats 
housed in specific germ-free (GF) conditions and weaned onto cereal diets displayed an upregulation of 
the interferon gamma (Ifng) and interleukin 15 (Il15) genes and a downregulation of the forkhead box 
P3 (Foxp3) gene [24]. Both Ifng and IL-15 are proinflammatory cytokines that promote T1DM in  
non-obese diabetic (NOD) mice [25], whereas Foxp3 is a master transcription factor that directs the 
differentiation and function of regulatory T cells and plays a central role in the inhibition of 
autoimmunity and suppression of physiological immune responses [26]. When BBdp rats were weaned 
onto cereal diets and housed in specific pathogen-free conditions (allowing gut microbiota growth), the 
rats also showed an upregulation of the lymphocyte-specific protein tyrosine kinase (Lck) gene [23]. 
Lck encodes tyrosine kinase/p56, a lymphocyte-specific protein involved in the initiation of T cell 
activation [27]. Finally, in this last condition, BBdp rats showed decreased expression of the cathelicidin 
antimicrobial peptide (Camp) gene. CAMP is a multifunctional antimicrobial effector and 
immunomodulatory host defense factor [28], which may alter the gut microbiota. 
Thus, for T1DM, nutrients can modify, alone or through changes in the gut microbiota, the expression 
of genes involved in the immune response. As a result, these changes may promote autoimmune 
responses in individuals predisposed to this condition. 
Recent advancements in human genetics have led to the identification of a relatively large number of 
T2DM-associated loci, more than 65 loci, many of which are novel [29] and increase the risk of T2DM 
by 10%–30%. However, their contribution to disease risk appears to be poor, and their predictive value 
is small because lifestyle plays a crucial role in T2DM development [30]. Studies that have investigated 
the gene-lifestyle interactions in T2DM have suggested that the biological effects of genetic 
predisposition may be partially or nearly completely abolished by a healthy lifestyle or lifestyle 
modifications [31]. Moreover, the contribution of the many genes and their relationship with numerous 
environmental factors confounds the common experimental designs used to identify gene-nutrient 
interactions. Thus, the experimental methods successfully applied to describe the genetic basis of 
monogenic diseases cannot be applied to complex traits, such as T2DM. To bypass this problem, a method 
called quantitative trait locus (QTL) analysis has been developed. This methodology allows the 
identification of regions of chromosomes that contribute to a complex trait [32]. QTLs are identified 
through statistical analysis of how frequently a region of a chromosome is associated with a measurable 
phenotype, e.g., plasma insulin levels or the homeostasis model assessment (HOMA) index. Finally, 
each of the genes within the QTLs may contribute different amounts to the trait. In this regard, SNPs 
may therefore be associated with small or large contributions to the complex trait [33]; the contribution 
will vary depending upon gene-nutrient interactions for the gene responsible for the QTL and whether 
that gene interacts with other genes in the genome. 
To date, more than 70 genes have been identified as involved in T2DM, primarily by association 
analysis [34]. In addition, via GWAS arrays, more than 100 SNPs have been identified for T2DM [35]. 
From the 50 novel loci associated with T2DM previously identified, more than 40 loci have been 
associated with T2DM-related traits, including fasting proinsulin, insulin and glucose (Table 1) [36–39]. 
However, for T2DM-related traits, such as the HOMA index or pancreatic β cell function, there are 
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virtually no published data examining the relationship between these traits or the genotype and 
environment interactions. Clinical investigations of some loci have suggested that the genetic 
components of T2DM risk act preferentially through β cell function [40]. Among all 40 loci associated 
with T2DM-related traits, only transcription factor-7-like 2 (TCF7L2) was shown to clearly contribute 
to T2DM risk [41]. Several studies in white European [42], Indian [43], Japanese [44], Mexican 
American [45] and West African [46] individuals have shown a strong association between TCF7L2 and 
T2DM. It is also noteworthy that these populations represent the major racial groups with a high 
prevalence of T2DM. In all populations, TCF7L2 showed a strong association, with the odds of 
developing T2DM increased by 30%–50% for each allele inherited. This finding indicates an 
approximately double odds ratio compared to most other diabetes susceptibility polymorphisms. 
TCF7L2 is a transcription factor involved in the Wnt signaling pathway that is ubiquitously expressed, 
and it has been observed that TCF7L2 risk alleles result in the overexpression of TCF7L2 in  
pancreatic β cells. This overexpression causes reduced nutrient-induced insulin secretion, which results 
in a direct predisposition to T2DM as well as an indirect predisposition via an increase in hepatic glucose 
production [47]. 
Table 1. Loci for T2DM-related traits identified by GWAS (in order of gene region). 
Loci 
NOTCH2 PSMD6 VGEFA CHCHD9 DCD CMIP 
ADAM30 CACNA1D CDKAL1 GAS1 HMGA2 WWOX 
SLC44A3 PPARG C6orf57 CAMK1D TMEM19 SGSM2 
SNX7 SYN2 TP53INP1 CDC123 LGR5 SRR 
PROX1 ZPLD1 GCK VPS26A TSPAN8 HNF1B 
CR2 PLS1 CPVL KIF11 IGF1 LPIN2 
PCNXL2 SLC2A2 JAZF1 HHEK HNF1A PAPL 
BCL11A PEX5L DGKB ADRA2A TRIAP1 PEPD 
THADA IGF2BP2 ACHE TCF7L2 SPRY2 GIPR 
GCKR ST6GAL1 GCC1 TCERG1L C14orf70 HNF4A 
ITGB2 PPP2R2C PAX4 CRY2 ATP10A HUNK 
RBM43 WFS1 KLF14 MADD C2CD4A PCBP3 
RND3 MAEA ZMAT4 KCNJ11 C2CD4B SEZ6L 
ITGB6 ZBED3 KCNU1 GALNTL4 VPS13C DUSP9 
RBMS1 AP3B1 CSMD1 LOC72903 LARP6  
GRB14 CETN3 SLC30A8 KCNQ1 HMG20A  
G6PC2 LOC72901 CDKN2A ARAP1 ZFAND6  
TMEFF2 PCSK1 CDKN2B MTNR1B AP3S2  
IRS1 KCNK16 PTRD BARX2 PRC1  
ADAMTS9 ZFAND3 GLIS3 TMEM45B FTO  
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3. Gene-Nutrient or Dietary Pattern Interactions in The Development of T2DM 
Recently, several studies have demonstrated the significant effects of genotype by environment 
interactions on T2DM [48,49]. However, further clarification of the role of these interactions at the 
genome-wide level could help predict disease risk more accurately and facilitate the development of 
dietary recommendations to improve prevention and treatment. Moreover, it would be very interesting to 
identify the specific dietary factors that are the most influential in the variation of a given T2DM-related 
phenotype and to what extent these dietary factors contribute to the phenotypic variation (Table 2). In 
particular, the dietary factors considered are macro- and micronutrients, foods and type of diets. A recent 
review present evidence on the dietary environment and genetics as risk factors for T2DM [50]. 
Table 2. Gene-nutrient or -dietary pattern interactions in the development of T2DM. 
Gene Region SNP Allele Change T2DM-Related Traits Dietary Factors References 
PPARG 3p25.2 rs1801282 C > G HOMA-IR index PUFA intake [51–53] 
TCF7L2 10q25.3 
rs12573128 A > G 
HOMA-IR index  
Oral glucose tolerance test 
Fat intake [54] 
rs12255372 G > T T2DM risk Carbohydrate intake [55] 
FTO 16q12.2 rs9939609 A > T T2DM risk Adherence to Mediterranean Diet [56,57] 
SLC30A8 8q24.11 
rs11558471 A > G Fasting glucose levels Zinc intake Magnesium intake [58,59] 
rs13266634 C > T T2DM risk 
Trans- and cis-beta-carotene 
and gamma-tocoferol intake 
[60] 
TRPM6 9q21.13 rs2274924 C > T Fasting glucose levels Magnesium intake [59] 
AS3MT 10q14.32 rs3740393 G > C Fasting glucose levels Magnesium intake [59] 
IRS1 2q36.3 rs2943641 C > T HOMA-IR index Vitamin D [61] 
GCKR 2p23 rs780094 C > T Fasting insulin levels Whole-grain intake [62] 
ADIPOQ * 3q27 
SNP276 G > T G > T Fasting glucose levels Carbohydrate intake [63–66] 
SNP45 G > T G > T T2DM lower risk Omega-3 intake [67] 
FABP2 4q28.31 
Ala54Thr 
polymorphism 
G > A HOMA-IR index SFA intake [68] 
CAV2 7q31.1 rs2270188 C > T T2DM risk SFA intake [69] 
PLIN 15q26.1 
11482 G > A G > A HOMA-IR index SFA fat and carbohydrates intake [70] 
14995 A > T A > T HOMA-IR index SFA fat and carbohydrates intake [70] 
CEBPA 19q13.1 rs12691 C > T 
Oral glucose tolerance test 
HOMA-IR index 
Fat intake [71] 
CLOCK 4q12 rs1801260 T > C 
Fasting insulin levels 
HOMA-IR index  
QUICKI index 
Fat and MUFA intake [72] 
CRY1 12q24.1 Rs2287161 G > C 
Fasting insulin levels 
HOMA-IR index  
QUICKI index 
Carbohydrate intake [73] 
SIRT1 10q21.3 
rs7895833 A > G Oral glucose tolerance test Famine in prenatal life [74] 
rs1467568 A > G Oral glucose tolerance test Famine in prenatal life [74] 
* Adiponectin (ADIPOQ). 
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3.1. Most Relevant T2DM Susceptibility Genes 
Gene and environment interaction studies have shown a nice association between variants in 
peroxisome proliferator-activated receptor gamma (PPARG), TCF7L2 and fat mass and obesity-associated 
protein (FTO) genes, a Western dietary pattern and T2DM. 
Interestingly, a proline to alanine substitution (Pro12Ala, rs1801282) in PPARG has been implicated 
in T2DM. The less frequent PPARG Ala12 variant reduces the risk of T2DM and is positively associated 
with insulin sensitivity [51]. Specific dietary factors, such as unsaturated fatty acids, which bind and 
upregulate PPARG, have been studied for gene and environment interactions [75]. In particular, some 
studies indicate Ala12 carriers may be more responsive to the beneficial effects of unsaturated fat and 
less sensitive to the adverse effects of total and saturated fat on glucose homeostasis compared to Pro12 
homozygotes [52,53] (Table 2). 
In the case of TCF7L2, it has been shown that diets with a low glycemic load reduce the risk of T2DM 
conferred by TCF7L2 [55,76]. In addition, TCF7L2 risk variant carriers may reduce their susceptibility 
to T2DM through dietary modifications, although this may require a much more intensive dietary 
regimen compared to non-risk carriers [77–79]. Moreover, the interaction between TCF7L2 rs12573128 
and dietary fat intake was shown to influence insulin sensitivity and glucose tolerance [54]. Finally, in 
the Nurses’ Health Study, 1114 cases with T2DM and 1915 controls were genotyped for TCF7L2 
(rs12255372), and dietary intake was assessed with a semi-quantitative food frequency questionnaire. 
The results demonstrated that carbohydrate quality and quantity modified the risk of T2DM, which 
indicates that changes in risk attributable to the TCF7L2 variant are increased under conditions of higher 
insulin demand [55] (Table 2). 
The FTO gene has been consistently associated with obesity risk. However, the association between 
obesity risk alleles with T2DM remains controversial. A recent study aimed to determine whether these 
associations could be modulated according to the level of adherence to the Mediterranean diet. In this 
regard, a case-control study including 3430 T2DM cases and 3622 non-diabetic subjects, with no 
differences in body mass index (BMI), was performed. This study identified consistent gene-diet 
interactions with adherence to the Mediterranean diet for the FTO-rs9939609 variant. In addition, when 
adherence to the Mediterranean diet was low, carriers of the variant alleles showed a higher T2DM risk. 
In contrast, when adherence to the Mediterranean diet was high, these associations disappeared [56]. 
Another study demonstrated that patients with T2DM, who were carriers of the AA genotype of FTO 
rs9939609, showed increased fat and decreased fiber consumption, independent of BMI [57] (Table 2). 
3.2. Other T2DM Susceptibility Genes 
There are other studies that have established gene and dietetic interactions related to T2DM (Table 2). 
One of these genes is solute carrier family 30 (zinc transporter), member 8 (SLC30A8). The protein 
encoded by this gene is a zinc efflux transporter involved in the accumulation of zinc in intracellular 
vesicles. This gene is expressed at a high level only in the pancreas, particularly in the islets of Langerhans. 
The encoded protein colocalizes with insulin in the secretory pathway granules of insulin-secreting  
INS-1 cells [80]. In a 14-cohort meta-analysis that assessed the interaction of 20 genetic variants known 
to be related to glycemic traits and zinc metabolism with dietary zinc intake, as well as a 5-cohort  
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meta-analysis that assessed the interaction with total zinc intake on fasting glucose levels in individuals 
of European ancestry without diabetes, a significant association of total zinc intake with lower fasting 
glucose levels was identified. However, the association with dietary zinc intake was not significant. 
Thus, a nominally significant, yet plausible, interaction between total zinc intake and the SLC30A8 
rs11558471 variant on fasting glucose levels was observed. This result suggests a stronger inverse 
association between total zinc intake and fasting glucose in carriers of the fasting glucose-raising allele 
compared with non-carriers [58]. Furthermore, in a case-control study of 1796 participants (218 newly 
diagnosed with impaired glucose regulation, 785 newly diagnosed with T2DM and 793 with normal 
glucose tolerance test), the C allele of SLC30A8 rs13266634 was associated with higher odds of T2DM, 
whereas higher plasma zinc was associated with lower odds. Moreover, the inverse association of plasma 
zinc concentrations with T2DM was modified by SLC30A8 rs13266634 [81]. In a large-scale interaction 
study of 15 reports from the CHARGE (Cohorts for Heart and Aging Research in Genomic 
Epidemiology) Consortium, which included data from up to 52,684 participants of European descent 
without known diabetes, cross-sectional associations of dietary magnesium intake with fasting glucose 
and insulin and the interactions between magnesium intake and SNPs related to fasting glucose, insulin 
or magnesium on fasting glucose and insulin were analyzed. In this study, it was determined that 
rs11558471 in SLC30A8 showed a nominal interaction with magnesium consumption and fasting 
glucose [59]. It was also observed that magnesium consumption had a nominal interaction with 
rs2274924 in the magnesium transporter-encoding transient receptor potential cation channel, subfamily 
M, member 6 (TRPM6) and with arsenic (+3 oxidation state) methyltransferase (AS3MT) rs3740393 near 
cyclin M2 (CNNM2) related to fasting glucose [59] (Table 2). A significant interaction between SLC30A8 
rs13266634 and three nutrients (trans- and cis-beta-carotene and gamma-tocopherol) was also  
identified [60]. Another study also explored the relationship between the insulin receptor substrate 1 
(IRS1) variant rs2943641 and circulating levels of 25-hydroxyvitamin D (25(OH)D). Women 
homozygous for the minor allele rs2943641T with higher circulating 25(OH)D showed a lower risk of 
insulin resistance and T2DM compared to carriers of the major allele (rs2943641C) [61] (Table 2).  
Gene-whole grain intake interactions have also been established for the glucokinase regulatory protein 
(GCKR) variant rs780094 in a meta-analysis of 14 cohort studies; this study demonstrated that dietary 
whole grain intake potentially interacts with the cited variant. In subjects with the insulin-raising allele 
of rs780094, greater whole grain intake was associated with a smaller reduction of fasting insulin compared 
to individuals with the non-risk allele [62] (Table 2). Interactions of variants of the gene adiponectin 
with carbohydrate intake have also been explored [63]. In oriental individuals, the T allele of common 
adiponectin SNP276 G > T and SNP45 G > T has been associated with T2DM in Japanese individuals [64], 
whereas only SNP276 G > T has been associated with T2DM in Taiwanese patients [65]; the G allele of 
both SNPs has been associated with several components of the metabolic syndrome in non-obese and 
non-diabetic Korean men [66] (Table 2). Therefore, the difference in susceptibility of this SNP may be 
the result of different environmental factors, such as diet. Significant dose-response interactions were 
identified between the SNP276 G > T polymorphism and the dietary intake of carbohydrate. This 
previous study demonstrated the gene-nutrient interactions between the SNP276 G > T polymorphism 
and the level of carbohydrate intake modulated plasma fasting blood glucose and glycosylated 
hemoglobin (HbA1C) [63]. Moreover, adiponectin SNP45 G > T individuals who had a high intake of 
n-3 polyunsaturated fatty acids (PUFAs) showed a decreased risk of T2DM [66,67] (Table 2). Intestinal 
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fatty acid-binding protein 2 (FABP2) Ala54Thr polymorphism, fat intake and insulin sensitivity have 
also been studied, and it was shown that insulin sensitivity was decreased in subjects with the Thr54 
allele of the FABP2 polymorphism when saturated fatty acids (SFAs) were replaced by monounsaturated 
fatty acids (MUFAs) and carbohydrates [68] (Table 2). Finally, SNP-nutrient interaction effects between 
genes that encode fatty acid metabolism and lipid mobilization and dietary fat together with carbohydrate 
intake have been evaluated with respect to the risk of developing T2DM. In this regard, a significant 
relationship between the caveolin-2 (CAV2) rs2270188 TT genotype and fat and SAF intake with respect 
to T2DM has been observed [69] (Table 2). A significant gene-diet interaction between the perilipin 
(PLIN) 11482 G > A and PLIN 14995 A > T polymorphisms and dietary fat and carbohydrate intake 
has also been identified in the determination of insulin resistance in women. Of note, these gene-fat 
interactions were observed only for SFAs, but not for MUFAs or PUFAs [70] (Table 2). Another gene-
environment interaction that has been studied is the CCAAT/enhancer-binding protein alpha (CEBPA) 
rs12691 SNP and 6 diabetes-related traits (fasting glucose and insulin levels, disposition index, insulin 
sensitivity index, HOMA-insulin resistance (HOMA-IR) index and acute insulin response to glucose) 
following 12 weeks of 4 dietary interventions (i.e., high SFA diet, high MUFA diet, low-fat diet and 
low-fat-high-n-3 PUFA diet). The authors demonstrated that carriers of the minor A allele displayed 
impaired glucose metabolism measured by the disposition index, acute insulin response to glucose, 
insulin sensitivity index and HOMA-IR index compared with the G/G homozygotes [71] (Table 2). 
3.3. CLOCK Gene Variants Linked to Diabetes 
Dysregulation and genetic variations at the Circadian Locomotor Output Cycles Kaput (CLOCK) 
genes, which are responsible for the circadian system, have been associated with T2DM [82]. Two studies 
analyzed the gene-nutrient interaction between several CLOCK gene variants and diabetes-related traits. 
In this regard, one study focused on the associations between SNPs rs1801260, rs3749474 and 
rs4580704 with 3 diabetes-related traits (i.e., insulin concentration, HOMA-IR index and quantitative 
insulin sensitivity check (QUICKI) index) following one year of dietary intervention (i.e., 35% fat, 22% 
MUFAs vs. 28% fat, 12% MUFAs). The authors reported significant gene-diet interactions between 
rs1801260 SNP (for the major allele TT) following one year of a low-fat intervention. Subjects 
homozygous for TT displayed lower plasma insulin concentrations and HOMA-IR index and a higher 
QUICKI index [72] (Table 2). The other study analyzed the interaction between the cryptochrome 1 
(Photolyase-Like) (CRY1) rs2287161 SNP and 4 diabetes-related traits (fasting glucose and insulin, 
HOMA-IR index and QUICKI index). This study found that individuals homozygous for the minor C 
allele had an increased carbohydrate intake (% of energy intake) that was associated with a significant 
increase in HOMA-IR index and fasting insulin, as well as a decrease in QUICKI [73] (Table 2). 
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3.4. Importance of Genotype by Macronutrient Interactions for T2DM-Related Traits 
Recently, using genome-wide complex trait analysis, the genome-environment contribution of  
14 dietary factors (glycemic load, total energy, protein, total fat, SFA, MUFA, PUFA, n-3 PUFA,  
n-6 PUFA, n-3:n-6 PUFA, carbohydrate, alcohol intake, trans fat and fiber) to the total phenotypic 
variance of 4 T2DM-related traits (fasting glucose, fasting insulin, HOMA-IR and HOMA of β cell 
function) were analyzed [83]. This study showed that for insulin and HOMA-IR, significant  
genome-nutrient variance contributions of carbohydrate were observed. In fact, 25.1% and 24.2% of the 
heritability of fasting insulin and HOMA-IR, respectively, could be explained by the genome-environment 
interaction of carbohydrate intake with the whole genome. However, the heritability explained by the 
genome alone for fasting insulin and HOMA-IR were 20.2% and 20.9%, respectively. In addition, for 
HOMA of β cell function, n-6 PUFA significantly contributed to the genome-nutrient interactions.  
In this regard, 39.0% of the heritability of HOMA of β cell function could be explained by the genome-
environment interaction of n-6 PUFA with the genome, while the heritability explained by the main 
effect of the genome without these interactions was 18.7% for HOMA of β cell function [83]. 
Finally, genome-nutrient interactions during prenatal life can influence T2DM risk later in life. 
Indeed, it has been demonstrated that sirtuin (SIRT) 1 variants (rs7895833 and rs1467568) and prenatal 
exposure to famine significantly increased T2DM risk [74] (Table 2). 
Thus, studies performed during the last decade have provided strong evidence to support a  
diet-genome interaction as an important factor leading to the development of T2DM. 
4. The Effects of Nutrients on Gene Expression: Their Importance in DM 
The “omics” technologies have been extensively used in an attempt to define molecular events 
involved in the health effects of nutrients. These technologies provide the opportunity to identify novel 
gene, protein and nutrient interactions. However, although the application of these technologies has 
become more accessible, they generate a large amount of complex data, as a specific nutrient could 
theoretically interact with all genes in the human genome. 
It was previously reported that food intake is a key component that affects the incidence of DM. Thus, 
the identification and analysis of nutrient/gene interactions are necessary steps to understand DM 
etiopathogenesis. In general, nutrients can affect gene expression via different mechanisms: (i) directly; 
(ii) through their metabolites and (iii) through signal transduction molecules (Figure 1). 
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Figure 1. Nutrient-gene expression mechanisms. Nutrients present in food and diet can 
affect gene expression in a number of ways. They may directly act as ligands for transcription 
factors and change gene expression. Nutrients may be metabolized by different pathways, 
thereby modifying the concentration of substrates or intermediates that affect gene 
expression. Alternatively, the substrates or intermediates may act on or alter cell signaling 
pathways involved in gene expression. Moreover, nutrients may directly alter signal 
transduction pathways responsible for modifications in gene expression. Finally, the 
modifications in the signaling pathways, caused by nutrients, may modulate the metabolism 
of nutrients affecting gene expression. The modifications in gene expression may affect 
muscle, liver, pancreatic β cells, hypothalamus and adipose tissue, thereby regulating 
glucose homeostasis. The effects of these nutrient-gene interactions can be deleterious 
increasing DM risk and illness progression and complications or protective doing the 
opposite effects. 
 
4.1. Flavonoids-Gene Interactions in DM Pathogenesis 
Numerous studies employing cell culture and living experimental animals support a beneficial effect 
of dietary flavonoids on glucose homeostasis [84]. Moreover, human studies have indicated that higher 
consumption of anthocyanins, particularly from blueberries, apples and pears, was consistently 
associated with a lower risk of DM [85]. These compounds were shown to regulate carbohydrate 
digestion, insulin secretion, insulin signaling and glucose uptake in insulin-sensitive tissues through 
various intracellular signaling pathways [86]. 
Interestingly, flavan-3-ols are present in many fruits, teas, cocoa and chocolate, especially 
epigallocatechin gallate (EGCG), and have been shown to improve insulin secretory function and the 
viability of β cells under conditions of glucotoxicity. These effects were mediated, at least in part, 
through increased expression of insulin receptor (Ir) substrate-2 (Irs2), protein kinase B (Akt), the 
forkhead box protein O1 (Foxo1) and pancreatic duodenal homeobox1 (Pdx1) [87]. EGCG has also been 
shown to protect insulin-producing β cells from pro-inflammatory cytokine-induced cytotoxicity via the 
modulation of B Cell CLL/Lymphoma 2 (Bcl-2) expression [88]. In addition, EGCG supplementation 
at pharmacological doses (1% in diet) improved insulin secretion from pancreatic β cells and preserved 
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islet morphology in obese db/db mice by reducing the expression levels of carnitine palmitoyltransferase 1 
(L-Cpt-1) and the endoplasmic reticulum stress marker DNA-damage-inducible transcript 3 (Ddit3), as 
well as its downstream targets protein phosphatase 1, regulatory subunit 15A (Ppp1r15a) and  
cyclin-dependent kinase inhibitor 1A (Cdkn1a) [89]. Thus, collectively, EGCG functions in many 
different roles that are associated with beneficial effects on DM. These changes include improvements 
in insulin secretion, glucose uptake, insulin resistance, glucose tolerance, oxidative stress, inflammation 
and mitochondrial function. In this regard, EGCG functions through modifications in the expression of 
genes involved in multiple signaling pathways to exert beneficial effects in DM (Table 3). 
Table 3. Nutrient- or dietary pattern-gene interactions in the development of DM. 
Nutrient Gene Interaction Function Experimental Model References 
Flavonoids 
Epigallocatechingallate 
(EGCG) 
↑Irs2, ↑Akt, ↑Foxo1, ↑Pdx1 
↑Viability of β-cell,  
↑insulin secretion 
RIN-m5F cells [87] 
↑Bcl-2 ↓Apoptosis, ↑glucose uptake RINm5F cells [88] 
↓L-Cpt-1, ↓Ddit3, 
↓Ppp1r15a, ↓Cdkn1a 
↑Insulin secretion,  
preserve islet structure 
db/db mice [89] 
Naringin or hesperidin 
↑Gk (liver), ↑Glut4 (WAT), 
↑Pparγ 
↓Hyperglycemia db/db mice [90] 
Naringin ↑Pparγ, ↑Hsp 
↓Hyperglycemia, 
↓hyperinsulinemia,  
↓insulin resistance,  
↑β cell function 
HFD-STZ-induced 
T2DM rats 
[91] 
Anthocyanins 
↑Glut4 (WAT, muscle), 
↑Pparα, ↑Aco, ↑L-Cpt-1 
↓Hyperglycemia,  
↑insulin sensitivity 
T2DM mice [92] 
↓Lipogenic genes 
↓Hyperglycemia, 
↓hyperinsulinemia 
HFD-DM mice [93] 
Quercetin ↓Cdkn1a 
↓Hyperglycemia,  
↑insulin plasma levels,  
↑pancreatic cell proliferation 
STZ-induced DM mice [94] 
Luteolin, apigenin ↓iNos ↓Apoptosis RINm5F cells  [95] 
Genistein ↑Ccnd1, ↓iNos 
↓Hyperglycemia,  
↑glucose tolerance,  
↑insulin plasma levels 
STZ-induced DM mice [96] 
Another bioactive compounds 
Oleanolic acid 
↑Antioxidant enzymes genes, 
↑phase II detoxification 
enzymes genes, ↓NF-κB 
↑β-cell survival Pancreatic islets [97] 
Berberine 
↑Cyp7a1, ↑Igfbp1,  
↑cell cycle genes,  
↑NADPH metabolism genes 
↓Fasting glucose,  
↓insulin resistance 
Diabetic Zucker rats [98] 
↑CuZn-superoxide dismutase ↓Hyperglycemia 
STZ-nicotinamide 
diabetic mice 
[99] 
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Table 3. Cont. 
Nutrient Gene Interaction Function Experimental Model References 
Vitamins 
Vitamin D 
↓Islet cytokine and 
chemokine genes 
↓Insulitis NOD mice [100,101] 
Biotin 
↑Foxa2, ↑Pdx-1, ↑Hnf-4α, 
↑Ins, ↑Gk, ↑Cacna1d, ↑Acac 
↑Insulin secretion,  
↑islet function 
Mice [102] 
Riboflavin ↑IL-6 
↓Cytokines-induced 
inflammation 
NIT-1 cells [103] 
Nicotinamide ↑MafA ↑Insulin synthesis 
INS-1 cells,  
pancreatic islets 
[104] 
Amino acids 
Leucine ↑mTor ↑Growth and proliferation Pancreatic islets [105] 
Taurine 
↑Pdx1, ↑Sur-1, ↑Gk,  
↑Glut-2, ↑Ins 
↑Insulin secretion,  
↑insulin synthesis 
OF1 mice, pancreatic 
islets culture 
[106] 
L-glutamine ↑Pdx1, ↑Calcineurin, ↑Acac 
↑Insulin secretion, 
↑proliferation 
BRIN-BD11 beta-cells [107] 
Dietary fats 
Palmitate 
↓Ins ↓Insulin secretion Pancreatic islets [108] 
↓Pdx-1, ↓MafA ↓Insulin secretion  [109] 
HFD 
↓Gpx1 
↓Antioxidant defenses  
of β-cells 
C57BL/6J mice [110] 
↑Growth and development, 
↑oxidative metabolism,  
↑insulin processing and 
secretion, ↑signaling,  
↑redox status 
T2DM NZO-mice [111] 
CHFD plus HFD ↓Pdx-1, ↓MafA, ↓Nkx6.1 
↓Insulin secretion,  
↓insulin synthesis,  
↓β-cell survival 
NZO-mice [112] 
Lipoic acid ↑Frk, ↑Gk, ↑G6pc2, ↑Phox Protection against T2DM 
High fructose-fed 
Wistar rats 
[113] 
Oleic acid ↓NPY, ↓AgRP 
↓Food intake,  
↓glucose production, 
↓plasma glucose levels, 
↓insulin plasma levels 
Sprague-Dawley rats  
Sprague-Dawley or  
Zucker fatty rats 
[114,115] 
Naringin and hesperidin, the two major flavanones, are present in citrus fruits and have also been 
involved in protection against DM. For example, dietary supplementation with hesperidin or naringin 
(200 mg/kg) has been associated with anti-hyperglycemic effects in C57BL/KsJ-db/db mice following 
5 weeks of treatment. This effect may primarily be due to an increase in liver glucokinase (Gk) and 
adipocyte glucose transporter type 4 (Glut4) [90]. In these mice, naringin and hesperidin treatment also 
led to the activation of the fat and liver peroxisome proliferator activated receptor (Ppar) γ [90] (Table 3). 
In T2DM rats fed a high-fat diet (HFD) and administered low-dose streptozotocin (STZ) injection, 
naringin was shown to dose-dependently ameliorate hyperglycemia, hyperinsulinemia and insulin 
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resistance and improve β cell function. These effects were associated with increased expression of Pparγ 
and heat shock proteins (Hsp) in the livers of diabetic rats [91] (Table 3). However, to date, there remains 
a lack of data from clinical studies to support the anti-diabetic potential of these flavanones. 
In the case of anthocyanidins, the observed anti-diabetic action appears to extend beyond their 
antioxidant property. Bilberry anthocyanins improved hyperglycemia and insulin sensitivity in T2DM 
mice by downregulating the expression of gluconeogenic enzymes, upregulating the expression of 
Pparα, L-Cpt-1, Glut4 and aconitase (Aco) in the livers of bilberry-supplemented T2DM mice, as well 
as upregulating the expression of Glut4 in the white adipose tissue (WAT) of bilberry-supplemented 
T2DM mice [92]. Moreover, this anthocyanin was shown to downregulate the expression of  
retinol-binding protein 4 (Rbp4) in the visceral fat [90] (Table 3). Finally, other anthocyanidins are 
known to control improvements in glucose homeostasis in high-fat-diet T2DM mice by downregulating 
lipogenic gene expression [93] (Table 3). 
The most abundant flavonoids are flavonols, which are dispersed throughout plant-based foods. One 
of the most important dietary flavonols is quercetin. In STZ-induced DM mice, dietary supplementation 
with quercetin (0.5% in the diet for 2 weeks) lowered blood glucose and enhanced serum insulin 
concentrations. These effects were associated with the downregulation of genes associated with cell 
proliferation (Cdkn1a) in the liver and pancreas [94] (Table 3). 
The major dietary flavones are apigenin and luteolin, which are found in celery, parsley and many 
herbs. In RIN cells, apigenin and luteolin treatment protected these cells from cytokine-induced 
apoptosis through the inhibition of inducible nitric oxide synthase (iNos) expression [95] (Table 3). 
However, it is not clear whether this effect also occurs in the islets in vivo. 
The major dietary isoflavones are daidzein and genistein, which are primarily present in soy foods. 
In STZ-induced diabetic mice, it has been shown that genistein improved hyperglycemia, glucose 
tolerance and circulating insulin concentrations by increasing islet β cell proliferation, β cell mass and 
survival. These effects were a result of genistein-induced cyclin D1 (Ccnd1) expression, a major  
cell-cycle regulator required for growth in β cells, and reduced iNos expression [96] (Table 3). 
Together, these studies indicate that dietary flavonoids exert their anti-diabetic effects by regulating 
the expression of different genes involved in various cellular signaling pathways in the pancreas, liver, 
skeletal muscle and WAT. These genes regulate nutrient-induced insulin release, insulin sensitivity and 
β cell proliferation and survival. 
4.2. Bioactive Compounds-Gene Interactions in DM Pathogenesis 
In addition to flavonoids, other bioactive compounds possess antidiabetic potential, such as 
triterpenoids. One of the most widely studied compounds of this family is oleanolic acid [97]. This 
compound is present in more than 120 plants and is especially abundant in the olive leaf [116,117]. 
Oleanolic acid has been demonstrated to improve insulin response and preserve the functionality  
and survival of pancreatic β cells. These actions appear to be derived from its interaction with 
transduction pathways that modulate the expression of key defensive genes, in which nuclear factor 
(erythroid-derived 2)-like 2 (Nfe2l2 or Nrf2) plays a very important role. In this regard, oleanolic acid 
is a potent inducer of the expression of antioxidant enzymes and other phase II detoxification enzymes, 
as wells as a repressor of the nuclear factor of the kappa light polypeptide gene enhancer in B-cells  
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(Nf-κB) [97] (Table 3). Berberine is a quaternary ammonium salt of the protoberberine group of 
isoquinoline alkaloids and is the major active component of Rhizoma Coptidis. A meta-analysis study 
indicated that berberine appeared to generate antidiabetic effects via the reduction of hyperglycemia and 
dyslipidemia in T2DM [118]. In diabetic Zucker rats, berberine treatment has been shown to reduce 
fasting glucose and insulin resistance; in particular, the authors showed that berberine downregulated 
micro RNA 29-b (miR29-b) expression and upregulated a gene network involved in the cell cycle and 
intermediary and NADPH metabolism. Moreover, berberine normalized cytochrome P450, family 7, 
subfamily A, polypeptide 1 (Cyp7a1) and insulin-like growth factor binding protein 1 (Igfbp1) gene 
expression [98] (Table 3). Finally, in STZ-nicotinamide diabetic mice, berberine treatment lowered 
blood glucose levels, and these authors also demonstrated increased hepatic CuZn-superoxide dismutase 
expression [99] (Table 3). 
4.3. Vitamins-Gene Interactions in DM Pathogenesis 
Another group of nutrients with anti-diabetic properties are vitamins. For example, it has been 
demonstrated that vitamin D may improve β cell function by limiting chemokine expression, partially 
normalizing the expression of major histocompatibility complex (MHC) class I molecules and decreasing 
the density of MHC class I proteins on β cells [100] (Table 3). In addition, a very recent study demonstrated 
that vitamin D protects murine and human pancreatic islets against inflammation-induced β cell 
dysfunction and death. Vitamin D modifies the expression of approximately 250 genes, particularly genes 
related to functional groups involved in immune responses, chemotaxis, cell death and pancreatic β cell 
function/phenotype [101]. Low concentrations of a vitamin complex (ascorbic acid, β-carotene and  
α-tocopherol) were shown to reduce the expression of nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase subunits, superoxide dismutase and catalase genes in diabetic patients [119]. Moreover, 
eight weeks of biotin supplementation in mice increased the expression of forkhead box A2 (Foxa2), 
Pdx1, hepatocyte nuclear factor 4α (Hnf-4α), insulin (Ins), glucokinase (Gk), calcium channel, voltage-
dependent, L type, alpha 1D subunit (Cacna1d) and acetyl-CoA carboxylase (Acac). These findings 
provide evidence for how biotin enhances insulin secretion and the expression of genes that favor islet 
function [102] (Table 3). In an insulinoma cell line (NIT-1) and murine islets, riboflavin treatment 
prevented the cytokine-induced increase in IL-6 mRNA expression [103] (Table 3). Nicotinamide also 
induced insulin gene expression in INS1-1 β cells via an increase in v-maf avian musculoaponeurotic 
fibrosarcoma oncogene homolog A (MafA) gene transcription [104] (Table 3). 
4.4. Amino Acids-Gene Interaction in DM Pathogenesis 
Amino acids are capable of direct modulation of insulin secretion and/or contribution to the maintenance 
of β cell function, which results in improved insulin release [120]. Amino acids, in addition to their effects 
on insulin secretion, may influence gene and protein expression in pancreatic islets (Table 3). For 
example, amino acid supplementation with taurine or leucine in control and malnourished mice increased 
the expression of genes and proteins essential for the insulin secretory process [120]. Leucine is the most 
effective amino acid in activating the mechanistic target of rapamycin (serine/threonine kinase) (mTor) 
complex [105]. As mTor is a key regulator of cell growth and proliferation [121], its activation is 
important in conditions of elevated demand for insulin, such as insulin resistance. Moreover, several 
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studies have shown that branched-chain amino acids play an important role in the regulation of protein 
synthesis via the activation of mTOR in pancreatic β cells [122]. Taurine is a conditionally essential 
amino acid in humans that is involved in the control of glucose homeostasis; this effect was shown to be 
a result of increased insulin, sulfonylurea receptor-1 (Sur-1), Gk, glucose transporter type 2 (Glut-2), 
proconvertase and Pdx1 gene expression [106]. In the case of L-alanine and L-glutamine, dependent 
regulation of the expression of genes related to β cell signal transduction, metabolism and apoptosis has 
been observed, including some key metabolic genes, including ATP citrate lyase and catalase [123]. 
Moreover, L-glutamine strongly upregulates calcium binding proteins (calcineurin) [107]; this 
upregulation is important because calcineurin is a key activator of the nuclear factor of activated T cells 
(Nfat) in pancreatic β cells [124], and Nfat activation promotes β cell proliferation and the expression of 
metabolic enzyme genes [107]. Finally, L-glutamine induces dependent upregulation of Pdx1 and Acac 
expression [107]. 
4.5. Dietary Fat-Gene Interactions and Their Role in T2DM 
Dietary fats also have important effects on gene expression in pancreatic β cells (Table 3). It is well 
known that consumption of a HFD is associated with an increased risk of T2DM [125]. However, the 
effects of fat on gene expression are varied. Following chronic exposure of β cells to palmitate, the 
inhibition of glucose-induced expression of prepro-insulin, as well as important transcription factors 
such as Pdx1 and MafA, caused β cell failure [108,109]. In addition, C57BL/6J mice fed a HFD  
(58% of calories from fat) showed a downregulation of glutathione peroxidase gene (Gpx1), which  
has been implicated in the antioxidant defenses of β cells [110]. Interestingly, Gpx1 regulates  
the expression of MafA, which is important in the regulation of insulin expression [110]. Thus,  
HFD-induced decreased expression of Gpx1 may be important in the pathogenesis of T2DM. An 
intriguing issue is that different mouse strains have distinct responses to a HFD diet when considering 
pancreatic β cell adaptation and insulin resistance. To investigate the role of different gene variants on 
these differences, the gene expression profile between C57BL/6J and AKR/J mice, which are both prone 
to HFD-induced metabolic syndrome, were analyzed following 12 weeks of HFD intake. Islets from 
HFD-fed AKR/J mice showed 202 genes upregulated and 270 genes downregulated compared to HFD-
fed C57BL/6j mice. A subsequent analysis indicated that the most profound differences observed were 
in genes related to secreted proteins, membrane receptors, extracellular matrix proteins and lipid 
metabolism [126]. An interesting study evaluated the diet-dependent genome-wide gene expression 
patterns of New Zeeland Obese (NZO) mice following a carbohydrate-free high fat-diet (CHFD) or a 
normal HFD [111]. NZO mice fed a HFD developed T2DM; however, when the mice were fed a CHFD, 
they did not develop T2DM [111]. In the islets of HFD- and CHFD-fed mice, 2109 genes were 
differentially expressed, showing changed of at least 1.5-fold. In response to a HFD, 1496 genes were 
upregulated and 613 genes were downregulated. In the HFD group, gene expression changes were 
associated with growth and development, such as cyclin-dependent kinase inhibitor 1b (Cdkn1b), purine 
rich element binding protein A (Pura), dachshund 1 (Dach1), tetraspanin 8 (Tspan 8) and paired box 
gene 6 (Pax6). Genes involved in insulin production and secretion, such as proprotein convertase 
subtilisin/kexin type 1 (Pcsk1), proprotein convertase subtilisin/kexin type 2 (Pcsk2), ribosomal protein 
S27-like (Rps27l), proteasome subunit beta type 7 (Psmb7), vesicle-associated membrane protein 8 and 
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5 (Vamp8 and Vamp5) and vesicle transport through interaction with t-SNAREs 1B homologue (Vti1b), 
were also differentially regulated. In addition, genes involved in the cellular redox state, such as 
thioredoxin interactin protein (Txnip), catalase (Cat), Gpx1 and peroxiredoxin 4 and 5 (Prdx4 and 
Prdx5), were also increased in the islets of HFD animals [126]. Moreover, genes related to signaling 
were also upregulated, which primarily included cholecystokinin (Cck), RAS-homologue enriched in 
brain (Rheb) and dual specificity phosphatase 6 (Dusp6); these changes represented a greater than 4-fold 
increase. Finally, regarding genes related to metabolism, genes with a larger than 4-fold upregulation 
included GDP-mannose 4, 6-dehydrate (Gmds), NADH dehydrogenase (ubiquinone), 1 alpha subcomplex 
1 (Ndufa1), squalene epoxidase (Sqle), ATP synthase H+ transporting mitochondrial F1 complex beta 
subunit (Atp5b), phosphoribosyl pyrophosphate synthetase 1 (Prps1), succinate-CoA ligase GDP-forming 
alpha subunit (Suclg1) and paraoxonase 3 (Pon3). In the case of the liver, HFD-fed mice showed an 
upregulation of carbohydrate-responsive element-binding protein (Chrebp), pyruvate kinase liver and 
RBC (Pklr) and stearoyl-CoA desaturase (Scd1) [111]. In this study, the islets from mice that received 
a HFD or CHFD showed enhanced oxidative metabolism because the genes for the oxidative 
phosphorylation (OXPHOS) metabolic pathway were upregulated, which suggests an increased flux of 
fatty acid metabolism through mitochondrial oxidation, specifically in HFD-fed mice. Because 
OXPHOS is a source of reactive oxygen species (ROS), the increased formation of reactive oxygen 
species (ROS) can produce mitochondrial and β cell apoptosis. Indeed, the involvement of oxidative 
stress has been proposed in the lipotoxicity hypothesis of T2DM [127]. Furthermore, the gene expression 
of cellular redox state regulators was also upregulated in HFD-fed mice. In another study, NZO mice 
were first fed with CHFD for 18 weeks and then fed with HFD. Two days after the HFD, the islets 
showed decreased expression of Pdx1, MafA and NK6 homeobox 1 (Nkx6.1) [112], which are 
transcription factors important for β cell integrity and survival. 
Lipoic acid is an organosulfur compound that is derived from octanoid acid. Lipoic acid is a potent 
lipophilic free radical scavenger with antioxidant effects, which has been shown to decrease blood 
glucose levels and glycosylated hemoglobin (HbA1c) in T2DM patients [128]. In addition, this 
compound was shown to prevent the increased fructokinase (Frk), Gk, glucose-6-phosphatase (G6pc2) 
and p22 (Phox) gene expression observed in fructose-fed rats. Thus, the authors suggested that lipoic 
acid could prevent the transition from impaired glucose tolerance to T2DM [113] (Table 3). 
In the case of in vitro experiments with mouse and human islets cultured with high levels of palmitate, 
an alteration of genes involved in lipid metabolism, inflammation and oxidative stress has been  
observed [129–131]. 
4.6. Food-Gene Interactions in DM Pathogenesis: Human Studies 
Substantially fewer studies have been performed in humans concerning nutrient-gene interactions in 
pancreatic β cell function- or insulin sensitivity-related genes. In one study, human in vivo gene 
expression changes in peripheral blood mononuclear cells following an acute ingestion of virgin olive 
oil were evaluated in 11 healthy volunteers. These data showed short time-course changes in the 
expression of genes related to insulin resistance, such as ADAM metallopeptidase domain 17 (ADAM17), 
adrenoreceptor beta 2 (ADRB2), lipoic acid synthetase (LIAS), arachidonate 5-lipoxygenase-activating 
protein (ALOX5AP), thrombospondin receptor (CD36), O-linked N-acetylglucosamine transferase 
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(OGT) and PPARBP [132]. The effects of carbohydrates were also studied. In a parallel study design, 
47 subjects with metabolic syndrome were fed two different types of carbohydrates (a rye pasta diet with 
a low postprandial insulin response and an oat-wheat-potato diet with high postprandial insulin 
response). In the rye pasta diet group, the downregulation of 71 genes was observed; some genes were 
related to insulin signaling, such as downregulation of the insulin receptor and insulin-like growth factor 
binding protein 5 (IGFBP-5) genes. On the other hand, in the oat-wheat-potato diet group, the 
upregulation of 62 genes linked to stress, cytokine-chemokine-mediated immunity and the interleukin 
pathway was observed [133]. Finally, studies on the effects of calorie restriction in obese men who lost 
5% of their body weight showed a modification in the expression of 385 genes (158 upregulated and 
227 downregulated) in peripheral blood mononuclear cells; some of these genes were related to insulin 
sensitivity [134]. 
All these studies show that gene expression, in pancreatic islets, is very sensitive to nutrients and 
bioactive compounds present in food. The altered expression of genes involved in β cell nutrient sensing, 
insulin synthesis, cell cycle, survival/apoptosis and cell maintenance can impair β cell function and at 
the end facilitates β cell failure (Figure 2). 
4.7. Nutrient-Gene Interactions in Hypothalamus Are Also Involved in DM Pathogenesis 
Another important issue to be considered is that to completely determine the etiopathogenesis of 
T2DM, it is necessary to understand the physiological regulation of energy homeostasis. In the end, this 
is governed by the hypothalamus. The role of hypothalamus in diabetes has already been demonstrated. 
Okamoto et al. [135] showed that restoration of insulin-signaling in the β cell and liver was unable to 
entirely reverse insulin resistance in a full body insulin receptor knockout mice. In addition, neuron-specific 
insulin receptor knockout mice exhibited a decreased response to insulin and hyperinsulinemia [136]. 
Thus, the hypothalamus has the capacity to sense and respond to nutrients, such as glucose and fatty 
acids. This results in lowering food intake and hepatic glucose production, to ultimately control metabolic 
homeostasis [137]. In this regard, different levels of glucose concentrations are able to increase the 
expression of the anorexigenic proopiomelanocortin (POMC) gene, in hypothalamic neuronal cell  
lines [138]. In addition, Obici et al. [114] demonstrated that fatty acid metabolization participates in 
hypothalamus glucose homeostasis regulation. For example, the intracerebroventricular administration 
of the MUFA oleic acid reduces the hypothalamic expression of neuropeptide Y (NPY) and agouti-
related protein (AgRP) [114,115], which in turns lowers food intake and glucose production. This results 
in a decrease in plasma insulin and glucose levels. Thus, data generated in the past decade indicate that 
hypothalamus is a key regulator of glucose homeostasis by sensing nutrients such as fatty acids and 
glucose. These nutrients are able to modify the expression of genes involved in energy balance. The 
knowledge of the molecular mechanisms that link nutrient input and brain responses will help us to 
identify possible central targets to fight against T2DM. 
  
 
Nutrients 2014, 6 5356 
 
Figure 2. Effects of nutrients on β cell gene expression. Pancreatic β cells are able to sense 
dietary nutrients and respond to them releasing insulin. Different nutrients and their 
metabolites affect transcription of genes very important for maintenance of β cell function 
and integrity. Flavonoids upregulate the expression of genes involved in insulin synthesis, 
nutrient-induced insulin release and β cell proliferation and downregulate genes implicated 
in β cell apoptosis. Proteins positively regulate insulin synthesis, insulin release, β cell 
proliferation and growth upregulating the expression of mTOR, calcineurin and Pdx1. Fats 
upregulate OXPHOS genes leading to the generation of metabolic coupling factors critical 
for insulin exocytosis. On the other hand, a chronic exposure of β-cells to high levels of fats 
(mainly saturated fatty acids) induces excessive levels of ROS and pro-inflammatory 
cytokines, leading to an increased apoptosis. The upregulation of the expression of cytokine 
genes and genes involved in pro-inflammatory signaling pathways, together with the 
downregulation of genes implicated in the antioxidant defenses of β cells, contribute to  
β cell apoptosis. Moreover, chronic exposure to fats and their byproducts downregulate the 
expression of genes necessary for insulin synthesis, nutrient-induced insulin release, β cell 
integrity, maintenance and survival (Pdx1 and MafA). Impairment of β-cell function is a 
hallmark of pancreatic β-cell failure and may lead to development of DM. 
 
5. Epigenetics, Micro RNAs (miRNAs) and Diet: Are They Involved in DM? 
Previous epigenetic studies have focused on the heritable alteration of DNA and proteins, linking the 
DNA and histones, which induces modifications in chromatin structure without changing the nucleotide 
sequence. Modulations in gene expression can be caused by epigenetic mechanisms such as DNA 
methylation, histone modifications, small and non-coding RNAs [139]. Non-coding RNAs (ncRNAs) 
have been implicated in the epigenetic regulation of gene expression, and recent studies have shown that 
miRNAs can induce chromatin remodeling. miRNAs are single-stranded RNA molecules that range in 
size from 18 to 22 nucleotides. The mammalian genome encodes several hundred miRNAs that fine-tune 
gene expression through the modulation of target mRNAs [140]. These findings suggest that DNA 
methylation, histone modification and miRNAs may function in concert to regulate gene expression [141]. 
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Various diet and dietary interventions have been associated with epigenetic changes that alter cellular 
signaling [142]. The first insights regarding the importance of nutritional status in epigenetic changes 
and showing that these epigenetic changes could have heritable health consequences on a long-term 
scale were obtained from the Dutch Famine Cohort [143]. Studies with this cohort have shown that 
serious nutritional deprivation during pregnancy caused an increased risk of metabolic disorders in the 
offspring several decades later [144]. This period of maternal starvation was very significant and caused 
marked differences in disease outcomes; the first trimester of pregnancy was particularly vulnerable to 
disease outcome in adulthood. The studies from the Dutch Famine Cohort have provided two principal 
lessons. First, there is a critical developmental time window where dietary pattern can induce epigenetic 
changes; second, these epigenetic changes are passed to offspring. 
To better address these points, various animal models have been developed. For example, using  
HFD-T2DM male rats, the F1 female offspring showed reduced β cell area and insulin secretion, together 
with glucose intolerance, without changes in body weight [145]. The islets of the F1 female offspring 
showed differential expression of many genes involved in Ca2+, mitogen-activated protein kinase and 
Wnt signaling, apoptosis and cell cycle regulation [145]. Similarly, in pregnant C57BL6J mice, food 
deprivation resulted in β cell mass reduction and an increased risk of β cell failure in offspring [146]. 
DNA methylation profiling of human islets that originated from diabetic and non-diabetic donors 
showed DNA methylation in the promoter regions of 254 genes, where the vast majority of CpG sites 
were hypomethylated in islets from diabetic donors [147]. However, in vitro incubation of islets with  
30 mM glucose for 48 h did not induce methylation of several CpG sites tested [147]. 
Diverse dietary components, such as amino acids, carbohydrates, fatty acids, vitamins and 
phytochemicals, have been found to affect the expression profile of miRNAs or their functions [142].  
In addition, miRNAs have been shown to be involved in T2DM. For example, miRNAs play major roles 
in pancreatic islet development, β cell dysfunction, insulin synthesis and secretion and insulin  
resistance [148]. Studies based on miRNA microarray analysis have identified many different miRNAs 
involved in the pathology of both T1DM and T2DM; these miRNAs include miR-375, miR-29, miR-9, 
miR-124a, miR-195, miR-222, miR-126, miR-133a, miR-296, miR-96, miR-34a, miR-146b, miR-657, 
miR-30d, miR-103, miR-107, miR-1, miR-125, miR-27, miR-122, miR-320, miR-21 and miR-30a [148]. 
In addition, Let-7 family miRNAs are related to the insulin signaling pathway, glucose metabolism and 
insulin sensitivity [149]. Some miRNAs (Let-7 family, miR-27, miR-29, miR-103, miR-107 and  
miR-122) are also deregulated by polyphenols, such as EGCG, ellagitannin, resveratrol, genistein and 
quercetin [150]. In addition, miR-21 expression is altered in response to a HFD, PUFAS and caloric 
restriction [151], and miR-222 levels were shown to be increased following nutrient deprivation of folate 
and vitamin B [151]. The Let-7 family also exhibited decreased levels in the presence of fats, changes 
in the presence of glucose and increased levels in the presence of vitamin A derivatives and folate, 
methionine and choline deficiency [151]. 
6. Conclusions 
T1DM involves the specific autoimmune destruction of pancreatic β cells. The single most important 
genetic determinant of T1DM susceptibility is the human leukocyte antigen (HLA). However, HLA only 
explains approximately 60% of the genetic influence of T1DM. In addition, other non-HLA genetic 
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polymorphisms indicate that environmental cues, such as diet-related issues, contribute to this disease. 
One important challenge is to identify the specific food determinants that trigger β cell autoimmunity 
and the progression from persistent β cell autoimmunity to the clinical onset of illness. Apart from 
vitamin D, the early intake of cow’s milk and gluten, and the protective effects of breastfeeding, there is 
limited evidence that other nutrients may affect T1DM onset. In addition, the role of the gut microbiota 
in the etiology of T1DM has gained importance. It is also critical to understand the potential role of 
nutritional factors in the origin and progression of T1DM, as well as to identify polymorphisms that link 
dietary factors with the drivers of T1DM development. To progress in this direction, carefully  
well-designed longitudinal studies are needed to understand the relationships among nutrients, 
microbiota, polymorphisms, genetic susceptibility and autoimmunity. T2DM is multifactorial and arises 
from complex interactions between the genetic makeup and environment. To date, the underlying  
gene-nutrient interactions that cause T2DM are not completely understood. Because of the complex 
genetic picture of T2DM, the role of nutrients and dietary patterns in the etiopathogenesis of the disease 
and related traits will most likely be multifactorial at the molecular level. Certainly, different 
pathophysiological pathways involve nutrient-induced failure of β cells and insulin resistance. 
Moreover, newly identified factors, such as epigenetic modification and miRNAs, likely have a 
substantial role in the impact of nutrients in T2DM. The integration of an individual’s genetic 
predisposition, gene-nutrient interactions, epigenetic programing and the involvement of nutrients in this 
issue, together with the knowledge obtained at all “omic” levels, produce a complex puzzle; thus, a 
systems biology approach will be required to advance knowledge of the origin, progression, prevention 
and treatment of T2DM. This will imply a deeper characterization of patients at the omic and clinical 
levels, which includes as many nutrient and/or dietary patterns as possible and the integration of data in 
interaction networks. Furthermore, the intestinal microbiota should be considered, as well as food 
genomes. Another challenge will be to translate the large data set generated by the different omics 
approaches into concrete knowledge that could be useful in the discovery of early molecular events that 
occur in DM and the identification of better biomarkers and diagnostic tools. These factors should enable 
personalized approximations thorough tailored diets that may contribute to DM prevention, which is the 
biggest challenge in addressing the burden of DM. 
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